SLC18A2 and Parkinson disease: PET studies in a non-human primate model of Parkinson’s disease (PD) showed that a decreased VMAT2 function and the disruption of DA sequestration was an early and potent contributor to oxidative damage of dopamine neurons in PD pathogenesis (Chen et al. 2008).